Bausch + Lomb (NYSE:BLCO) Price Target Raised to $19.00

Bausch + Lomb (NYSE:BLCO) had its target price increased by stock analysts at Wells Fargo & Company from $18.00 to $19.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price points to a potential downside of 8.10% from the stock’s current price.

Several other analysts also recently weighed in on BLCO. Leerink Partners began coverage on shares of Bausch + Lomb in a research report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 price objective for the company. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research report on Monday, July 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Bausch + Lomb in a research report on Thursday. Citigroup reiterated a “buy” rating on shares of Bausch + Lomb in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Bausch + Lomb in a research report on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.54.

Bausch + Lomb Stock Up 1.3%

BLCO stock traded up $0.27 during trading on Thursday, hitting $20.67. 429,154 shares of the company’s stock were exchanged, compared to its average volume of 450,512. The business has a 50-day moving average price of $17.24 and a two-hundred day moving average price of $16.66. The stock has a market capitalization of $7.39 billion, a price-to-earnings ratio of -43.54, a PEG ratio of 0.55 and a beta of 0.56. Bausch + Lomb has a 52-week low of $14.44 and a 52-week high of $21.36. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79.

Bausch + Lomb (NYSE:BLCO) last announced its quarterly earnings results on Wednesday, October 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.21 by $0.13. The company had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a negative net margin of 3.21% and a positive return on equity of 4.14%. The firm’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.18 earnings per share. As a group, equities research analysts expect that Bausch + Lomb will post 0.81 EPS for the current year.

Insiders Place Their Bets

In other news, Director Eschenbach Andrew C. Von sold 12,500 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total value of $206,250.00. Following the completion of the sale, the director owned 69,792 shares in the company, valued at approximately $1,151,568. This trade represents a 15.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Frederick Munsch sold 52,900 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at $769,044.18. This represents a 53.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 71,459 shares of company stock worth $1,194,370 over the last ninety days. Corporate insiders own 1.45% of the company’s stock.

Hedge Funds Weigh In On Bausch + Lomb

A number of large investors have recently modified their holdings of the business. Roxbury Financial LLC acquired a new position in Bausch + Lomb during the third quarter worth $33,000. Royal Bank of Canada raised its position in Bausch + Lomb by 67.1% in the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after acquiring an additional 1,468 shares in the last quarter. State of Wyoming lifted its holdings in Bausch + Lomb by 6.9% in the third quarter. State of Wyoming now owns 13,772 shares of the company’s stock valued at $234,000 after acquiring an additional 887 shares during the period. Handelsbanken Fonder AB lifted its holdings in Bausch + Lomb by 5.3% in the second quarter. Handelsbanken Fonder AB now owns 22,000 shares of the company’s stock valued at $364,000 after acquiring an additional 1,100 shares during the period. Finally, Squarepoint Ops LLC boosted its position in shares of Bausch + Lomb by 31.7% during the 2nd quarter. Squarepoint Ops LLC now owns 24,379 shares of the company’s stock worth $404,000 after purchasing an additional 5,861 shares in the last quarter. 11.07% of the stock is owned by hedge funds and other institutional investors.

Key Bausch + Lomb News

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Raised 2026 guidance: Bausch + Lomb increased its revenue outlook to $5.450 billion-$5.550 billion and adjusted EBITDA guidance to $1.090 billion-$1.140 billion, citing continued momentum from Vision ’27. Bausch + Lomb raises 2026 guidance
• Positive Sentiment: Beat earnings expectations: Third-quarter adjusted EPS was $0.34, well above the $0.21 consensus estimate and up from $0.18 in the year-earlier quarter. The earnings upside was a key driver of the bullish reaction. Bausch + Lomb surpasses Q3 earnings and revenue estimates
• Positive Sentiment: Revenue exceeded forecasts: Quarterly revenue reached approximately $1.375 billion-$1.38 billion, ahead of the $1.37 billion consensus and approximately 7.3% higher year over year. Strong eye-care growth supported the performance. Bausch + Lomb third-quarter earnings results
• Positive Sentiment: Improved profitability: The company swung to a third-quarter profit on an adjusted basis, with earnings substantially ahead of expectations. Management’s earnings call emphasized ongoing operating momentum and the Vision ’27 plan. Bausch + Lomb Q3 2026 earnings call transcript
• Neutral Sentiment: Despite the strong adjusted results, Bausch + Lomb continues to report a negative net margin, so investors will monitor whether revenue growth and the Vision ’27 initiatives translate into sustained GAAP profitability.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.